FibroGen Competitors and Similar CompaniesClear all
FibroGen's competitors and similar companies include Lung Therapeutics, Innoprot, PhoenixBio and Lineage Cell Therapeutics.
 FibroGen FibroGen is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to treat serious unmet medical needs. |  Lung Therapeutics Lung Therapeutics is a biopharmaceutical company developing medicines for unmet medical needs in fibrosis and lung disease. |  Innoprot Innoprot is a biotechnology company that provides products and technologies for cell-based assays in drug discovery and development. |  PhoenixBio PhoenixBio (株式会社フェニックスバイオ) is a company that provides contract study services for drug discovery and development. |  Lineage Cell Therapeutics Lineage Cell Therapeutics (formerly known as BioTime) is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. | |
Founding Date | Founding Date 1993 | Founding Date 2013 | Founding Date 2007 | Founding Date 2002 | Founding Date 1990 |
Type | Type Public | Type Private | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations San Francisco, US HQ | Locations Austin, US HQ | Locations Derio, ES HQ | Locations Higashihiroshima, JP HQ New York, US | Locations Carlsbad, US HQ Jerusalem, IL Alameda, US |
Employees | Employees 53115% increase | Employees 10 | Employees 16 | Employees 70 | Employees 5530% decrease |
Valuation ($) | Valuation ($) 30.7 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 10.9 m | Valuation ($) 166.5 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $6.4m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) ¥1.5b (FY, 2025) | Revenue (est.) $14.6m (FY, 2025) |
Cost of goods | Cost of goods $556k (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods ¥405.1m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit $5.9m (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit ¥1.1b (FY, 2025) | Gross profit N/A |
Net income | Net income $183.5m (FY, 2025) | Net income N/A | Net income N/A | Net income (¥448.9m) (FY, 2025) | Net income ($63.4m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 53.9m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 80.9m |
For sources of this data, please see the company profile
View Company Profiles
Lung Therapeutics
HQ
Austin, US
Employees
10
Lung Therapeutics is a biopharmaceutical company developing medicines for unmet medical needs in fibrosis and lung disease.
View companyInnoprot
HQ
Derio, ES
Employees
16
Innoprot is a biotechnology company that provides products and technologies for cell-based assays in drug discovery and development.
View companyPhoenixBio
HQ
Higashihiroshima, JP
Employees
70
PhoenixBio (株式会社フェニックスバイオ) is a company that provides contract study services for drug discovery and development.
View companyLineage Cell Therapeutics
HQ
Carlsbad, US
Employees
55↓ 30% decrease
Lineage Cell Therapeutics (formerly known as BioTime) is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases.
View company